Best Options Strategy for STOK
Looking for the best options strategy for Stoke Therapeutics, Inc. (STOK)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live STOK option chain right now, and a simple map from your view on STOK to the strategy that fits it. Model any of them in the calculator before you trade.
About STOK
Stoke Therapeutics, Inc. (STOK) is a major company in Biotechnology. Options traders on STOK tend to watch , since these can drive large moves in the share price.
About Stoke Therapeutics, Inc.
Stoke Therapeutics develops treatments for rare genetic disorders where patients don't produce enough of a critical protein. The company's main innovation is a technology platform called TANGO that creates antisense drugs designed to increase protein levels in people with these conditions. The approach targets haploinsufficiency diseases—disorders caused by insufficient gene expression—particularly in the nervous system and eyes. The company's most advanced program is Zorevunersen, currently in late-stage trials for Dravet syndrome, a severe childhood epilepsy. It also has STK-002 in earlier testing for autosomal dominant optic atrophy, a condition that causes progressive vision loss. Beyond these internal programs, Stoke has established partnerships to expand its pipeline.
The company generates revenue through partnerships and licensing deals that fund its research operations. Biogen has signed on to develop and commercialize Zorevunersen globally, providing both funding and commercial infrastructure for that program. Stoke also works with Acadia Pharmaceuticals on discovering and developing RNA-based therapies for genetic neurodevelopmental diseases. Founded in 2014 as ASOthera…
Today's top-scoring strategy for STOK
Our engine ranks defined-risk strategies on the live STOK chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $26 | $0.06 |
| Sell | 1× | PUT | $28 | $0.25 |
| Sell | 1× | CALL | $34 | $0.26 |
| Buy | 1× | CALL | $36 | $0.06 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Strategy analysis
Greeks vs price
Price × volatility (today)
| −30% | −15% | IV | +15% | +30% | |
|---|---|---|---|---|---|
| $39 | −$144 | −$135 | −$127 | −$120 | −$114 |
| $37 | −$119 | −$110 | −$102 | −$97 | −$93 |
| $36 | −$77 | −$73 | −$71 | −$70 | −$70 |
| $34 | −$28 | −$33 | −$37 | −$42 | −$47 |
| $32 | $10 | −$0 | −$11 | −$21 | −$30 |
| $31 | $25 | $13 | $0 | −$12 | −$24 |
| $29 | $13 | $1 | −$11 | −$22 | −$32 |
| $28 | −$30 | −$37 | −$42 | −$48 | −$54 |
| $26 | −$92 | −$88 | −$86 | −$84 | −$84 |
| $25 | −$140 | −$132 | −$125 | −$120 | −$115 |
| $23 | −$158 | −$154 | −$149 | −$144 | −$139 |
Illustrative example at STOK's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
STOK is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on STOK currently price in about 32% implied volatility, versus roughly 46% the stock has actually realised over the past month. That makes options relatively cheap — an edge for strategies that buy premium, such as long calls, long puts and debit spreads.
Off that volatility, the options market is pricing a move of about ±$3.03 (±10%) in STOK by 2026-09-18 — a range of roughly $27.9 to $33.96. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on STOK trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
STOK insider trading activity (SEC Form 4)
Open-market insider transactions at STOK over roughly the last six months, from SEC Form 4 filings. Open-market buys are the rarer, more telling signal — routine selling under pre-arranged plans is common, so read a net-selling figure with that in mind.
| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| Ticho Barry | Sell | 1,269 | $37K | 2026-08-03 |
| Ticho Barry | Sell | 5,907 | $171K | 2026-08-03 |
| Ticho Barry | Sell | 500 | $17K | 2026-07-01 |
| Ticho Barry | Sell | 6,728 | $219K | 2026-07-01 |
| Allan Jonathan | Sell | 1,457 | $44K | 2026-06-16 |
| Ticho Barry | Sell | 1,795 | $55K | 2026-06-01 |
Source: SEC Form 4 filings via Finnhub. Open-market purchases (P) and sales (S) only — grants, option exercises, gifts and tax withholding are excluded. Informational context, not investment advice.
Earnings & IV crush
STOK's next earnings report is due around November 3, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $2.1B
- Beta (vs market)
- 1.23
- 52-week range
- $12.75–$40.22 (66% up the range)
- Short interest
- 26.2% of float · 14.7 days to cover
With 26.2% of STOK's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for STOK
Start with your outlook on STOK, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while STOK stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →⧉ Embed this free calculator on your site →
How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open STOK in the free calculator →
Frequently asked questions
What is the best options strategy for STOK?
It depends on your outlook. Bullish traders often use a long call or bull call spread on STOK; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are STOK options liquid enough to trade?
Stoke Therapeutics, Inc. (STOK) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade STOK options?
Buying a single STOK call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade STOK or any security. Do your own research.
What does Stoke Therapeutics, Inc. do?
Stoke Therapeutics, Inc. (STOK) operates in the Biotechnology industry. The "About Stoke Therapeutics, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Stoke Therapeutics, Inc. pay a dividend?
We don't show a confirmed dividend yield for Stoke Therapeutics, Inc. here, so treat it as uncertain: before writing calls, check its current dividend and ex-dividend date with your broker — an approaching ex-dividend date can trigger early assignment on in-the-money short calls.
When does Stoke Therapeutics, Inc. next report earnings?
Stoke Therapeutics, Inc.'s next earnings are expected around November 3, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Price trend
Tickers related to STOK
Comparing STOK with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 45 Wiggins Avenue, Bedford, MA, 01730, United States
- Industry
- Biotechnology
- Employees
- 170
- CEO
- Mr. Ian F. Smith A.C.A., C.P.A.
- Phone
- 781 430 8200
- Website
- www.stoketherapeutics.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.